Patient-reported Symptoms of Tenosynovial Giant Cell Tumors

Clinical Therapeutics

Volumn 38, Issue 4, 2016, Pages 778-793

  Gelhorn, Heather L ^a   Tong, Sandra ^b   McQuarrie, Kelly ^a   Vernon, Christina ^a   Hanlon, Jennifer ^a   MacLaine, Grant ^c   Lenderking, William ^a   Ye, Xin ^d   Speck, Rebecca M ^a   Lackman, Richard D ^e   Bukata, Susan V ^f   Healey, John H ^g   Keedy, Vicki L ^h   Anthony, Stephen P ⁱ   Wagner, Andrew J ^j   Von Hoff, Daniel D ^k   Singh, Arun S ^f   Becerra, Carlos R ^l   Hsu, Henry H ^b   Lin, Paul S ^b   Tap, William D ^g   more..

^a EVIDERA   (United States)

^b PLEXXIKON INC   (United States)

^c DAIICHI SANKYO CO   (Japan)

^d DAIICHI SANKYO INC   (United States)

^e Division of Female Pelvic Medicine and Reconstructive Surgery   (United States)

^f UCLA MEDICAL CENTER   (United States)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

ⁱ TEXAS ONCOLOGY   (United States)

^j DANA FARBER CANCER INSTITUTE   (United States)

^k TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^l BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

giant cell tumors of the tendon sheath (GCT TS); Key words pigmented villonodular synovitis (PVNS); patient reported outcomes (PRO); PROMIS; tenosynovial giant cell tumor (TGCT)

Indexed keywords

ANTIINFLAMMATORY AGENT; NARCOTIC AGENT; PEXIDARTINIB; STEROID;

ADULT; ARTHRALGIA; ARTHROSCOPY; ARTICLE; CANCER SURGERY; CLINICAL ARTICLE; CONTENT VALIDITY; ELBOW; FEMALE; FOREARM; GIANT CELL TUMOR; HIP; HUMAN; INTERVIEW; JOINT INSTABILITY; JOINT STIFFNESS; JOINT SWELLING; JOINT TUMOR; KNEE; MALE; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PIGMENTED VILLONODULAR SYNOVITIS; RANGE OF MOTION; RATING SCALE; SWELLING; SYNOVECTOMY; TELEPHONE INTERVIEW; TENOSYNOVIAL GIANT CELL TUMOR; TREATMENT OUTCOME; CLINICAL TRIAL; GIANT CELL TUMOR OF TENDON SHEATH; PATIENT-REPORTED OUTCOME;

ADULT; FEMALE; GIANT CELL TUMOR OF TENDON SHEATH; HUMANS; MALE; MIDDLE AGED; PATIENT REPORTED OUTCOME MEASURES; TREATMENT OUTCOME;

EID: 84961878264     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2016.03.008     Document Type: Article

References (25)

1. C.D.M. Fletcher, J.A. Bridge, P. Hogendoorn, and et al. WHO Classification of Tumours of Soft Tissue and Bone 4th ed 2013 IARC Press Lyon
2. M.D. Murphey, J.H. Rhee, R.B. Lewis, and et al. Pigmented villonodular synovitis: radiologic-pathologic correlation Radiographics 28 2008 1493 1518
3. V. Sharma, and E.Y. Cheng Outcomes after excision of pigmented villonodular synovitis of the knee Clin Orthop Relat Res 467 2009 2852 2858
4. B.W. Myers, and A.T. Masi Pigmented villonodular synovitis and tenosynovitis: a clinical epidemiologic study of 166 cases and literature review Medicine (Baltimore) 59 1980 223 238
5. Verschoor AJ, Bovee JVMG, van de Sande MAJ, Gelderblom H. Incidence and demographics of giant cell containing tumors in the Netherlands: a nationwide pathology database study. Paper presented at: Connective Tissue Oncology Society Annual Meeting; 2015; Salt Lake City, UT.
6. V. Ravi, W.L. Wang, and V.O. Lewis Treatment of tenosynovial giant cell tumor and pigmented villonodular synovitis Curr Opin Oncol 23 2011 361 366
7. B. Molena, P. Sfriso, F. Oliviero, and et al. Synovial colony-stimulating factor-1 mRNA expression in diffuse pigmented villonodular synovitis Clin Exp Rheumatol 29 2011 547 550
8. R.B. West, B.P. Rubin, M.A. Miller, and et al. A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells Proc Natl Acad Sci U S A 103 2006 690 695
9. J.S. Cupp, M.A. Miller, K.D. Montgomery, and et al. Translocation and expression of CSF1 in pigmented villonodular synovitis, tenosynovial giant cell tumor, rheumatoid arthritis and other reactive synovitides Am J Surg Pathol 31 2007 970 976
10. W.D. Tap, Z.A. Wainberg, S.P. Anthony, and et al. Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor N Engl J Med 373 2015 428 437
11. D.M. Thomas The growing problem of benign connective tissue tumours Lancet Oncol 16 2015 879 880
12. van der Heijden L, Facebook PVNS research group, van de Sande MAJ. Diffuse-type giant cell tumor of the knee and hip-first Facebook-based functional outcome and quality of life study after arthroscopic or open synovectomy in 71 patients. Paper presented at: 27th Annual Meeting of the European Musculo-Skeletal Oncology Society; 2014(a); Vienna, Austria.
13. L. van der Heijden, M.J. Mastboom, P.D. Dijkstra, and M.A. van de Sande Functional outcome and quality of life after the surgical treatment for diffuse-type giant-cell tumour around the knee: a retrospective analysis of 30 patients Bone Joint J 96-B 2014 1111 1118
14. F.G. Verspoor, A.A. Zee, G. Hannink, and et al. Long-term follow-up results of primary and recurrent pigmented villonodular synovitis Rheumatology (Oxford) 53 2014 2063 2070
15. D.L. Patrick, L.B. Burke, C.J. Gwaltney, and et al. Content validity-establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force Report: Part 1 - eliciting concepts for a new PRO instrument Value Health 14 2011 967 977
16. N. Bellamy, W.W. Buchanan, C.H. Goldsmith, and et al. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee J Rheumatol 15 1988 1833 1840
17. N. Bellamy WOMAC Osteoarthritis Index User Guide 2002 Version V Brisbane, Australia
18. C.S. Cleeland, and K.M. Ryan Pain assessment: global use of the Brief Pain Inventory Ann Acad Med Singapore 23 Mar 1994 129 138
19. PROMIS. Physical Function, a brief guide to the PROMIS Physical Function instruments. https://www.assessmentcenter.net/documents/PROMIS%20Physical%20Function%20Scoring%20Manual.pdf. Accessed November 12, 2015.
20. H. Boeije A purposeful approach to the constant comparative method in the analysis of qualitative interviews Quality and Quantity 36 2002 391 409
21. ATLAS.ti Scientific Software Development GmbH ATLAS.ti (software), version 6.0 2011 ATLAS.ti Scientific Software Development GmbH Berlin, Germany
22. B. Bruce, J.F. Fries, D. Ambrosini, and et al. Better assessment of physical function: item improvement is neglected but essential Arthritis Res Ther 11 2009 R191
23. D. Cella, S. Yount, N. Rothrock, and et al. The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative group during its first two years Med Care 45 2007 S3 S11
24. Food and Drug Administration Guidance for Industry on Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims Federal Register 74 2009 65132 65133
25. European Medicines Agency. Reflection Paper on the Regulatory Guidance for the use of Health Related Quality of Life (HRQL) Measure in the Evaluation of Medicinal Products. 2005. http://www.ispor.org/workpaper/emea-hrql-guidance.pdf. Accessed December 3, 2015.